Skip to main
CNMD
CNMD logo

CONMED (CNMD) Stock Forecast & Price Target

CONMED (CNMD) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 20%
Hold 80%
Sell 0%
Strong Sell 0%

Bulls say

Conmed Corp has demonstrated robust growth in its high-demand segments, particularly with the BioBrace product line, which is set for full FDA-approved release, signaling a promising expansion in rotator cuff repair offerings. Despite facing supply constraints, the Foot & Ankle segment achieved double-digit growth, reflecting resilience and a potential easing of operational challenges. Additionally, the company's conservative revenue guidance indicates a strategic focus on sustainable growth, suggesting management's confidence in a gradual improvement of top-line performance in the latter half of the year.

Bears say

Conmed Corp's stock has experienced a significant decline of approximately 27% year-to-date, reflecting ongoing struggles in the company's turnaround efforts. The company's recent pricing target has been reduced from $80 to $68, which indicates a downward adjustment in expectations based on its fiscal year 2025 earnings per share estimate of $4.46. Additionally, there has been observed capital weakness, particularly in international markets, attributed to challenging year-over-year comparisons rather than an overall slowdown in hospital capital budgets.

CONMED (CNMD) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 20% recommend Buy, 80% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CONMED (CNMD) Forecast

Analysts have given CONMED (CNMD) a Hold based on their latest research and market trends.

According to 5 analysts, CONMED (CNMD) has a Hold consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CONMED (CNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.